Primary Outcome Measures:
- To provide an IRB-approved mechanism for the collection of peripheral blood, urine, sputum and bone marrow samples from paid, volunteer donors for use in in vitro studies. [ Time Frame: Throughout the course of the study ] [ Designated as safety issue: No ]
- To provide adequate and complete informed consent to the donors of research blood samples, and to assure that the education, counseling and protection of the study subjects from research risks is performed in accordance with IRB, OHRP, and other... [ Time Frame: Throughout the course of the study ] [ Designated as safety issue: Yes ]
This protocol is designed to provide blood, urine, sputum, and bone marrow aspirate samples from paid, volunteer donors for use in in vitro studies of eosinophilia. Donors meeting standard blood, urine, and sputum donor eligibility criteria will be recruited to donate blood, urine, sputum, and/or bone marrow using conventional techniques. The investigational nature of the studies in which their samples will be used, as well as the risks and benefits of the donation process will be explained to all donors, and a signed informed consent document will be obtained. Donors will be compensated according to an established schedule based on the duration and discomfort of the donation. Samples provided through this protocol will be used solely for in vitro research. Blood, urine, sputum and bone marrow samples will be assigned a unique product number, and the study investigators listed on this protocol will serve as the custodians of the code that links the product with a donor's identity. The nature of the in vitro studies in which the specimens collected in this study will be used is not the subject of this protocol and will be described in general terms only, since it involves several IRB approved LPD protocols. This protocol is designed to assure adequate and complete informed consent, counseling and protection of the study subjects according to IRB, OHSR, OPRR and other applicable Federal regulatory standards.